Aplastic anemia evolving to myelodysplastic syndrome and later to a lymphoproliferative malignancy in a treated case of carcinoma breast: A case report emphasizing the importance of PET-CT in cutaneous T cell lymphoma

Document Type: Case Report

Authors

Department of Nuclear Medicine & PET/CT, Amrita Institute of Medical Sciences & Research Centre, Cochin, Kerala, India

Abstract

Although aplastic anemia (AA) and myelodysplastic syndrome (MDS) are separate entities with different management, distinction between the two can be difficult on morphological basis due to hypocellularity of bone marrow. MDS is one of the serious complications of AA. Karyotyping is definitive in the diagnosis of MDS. Better and robust investigations like 18F-Fluoro-deoxy-Glucose Positron Emission Tomography/Computed Tomography (18F-FDG PET-CT) are essential in high risk patients with haematological malignancies and in those relapsing within a short period of time after initiation of therapy or having refractory disease. It might be helpful in the development of individual treatment algorithms for these high-risk patients. There may be unique problems in hematological malignancies where the transformation of one pathology into another may be silent with no biomarkers that can predict this transformation e.g. transformation of MDS from AA. Studies have shown that immune suppression can lead to a variety of haematological and lymphoproliferative disorders which may co-exist. 18F-FDG PET-CT may be useful in identifying the primary or occult sites of malignancy and also can direct the site from which biopsy can be attempted. We present a patient with Carcinoma right breast who developed hematological and lymphoproliferative disorders during the course of her treatment. In this case, AA transformed to MDS with abnormal karyotype (chromosome 9 mutation) and then progressed further to manifest cutaneous T cell lymphoma before patient succumbed to her illness. Immune mediated suppression of haemopoiesis has been considered the most important mechanism in this case.‎

Main Subjects


  1. Young NS. Pathophysiologic mechanisms in acquired  aplastic anemia. Hematology Am Soc Hematol Educ Program. 2006:72-7.
  2. Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Leaverton PE, Shapiro S, Young NS. The epidemiology of aplastic anemia in Thailand. Blood. 2006 Feb 15;107(4):1299-307.
  3. Gupta V, Kumar A, Saini I, Saxena AK. Cytogenetic profile of aplastic anaemia in Indian children. Indian J Med Res. 2013 Mar;137(3):502-6.
  4. Jamil B, Nicholls K, Becker GJ, Walker RG. Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation. 1999 Nov 27;68(10):1597-603.
  5. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA; HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007 Jun 20;99(12):962-72.
  6. Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol. 2010 Jul;6(4):621-31.
  7. Burad DK, Therese MM, Nair S. Peripheral T-cell lymphoma: frequency and distribution in a tertiary referral center in South India. Indian J Pathol Microbiol. 2012 Oct-Dec;55(4):429-32.
  8. Thangavelu M1, Finn WG, Yelavarthi KK, Roenigk HH Jr, Samuelson E, Peterson L, Kuzel TM, Rosen ST. Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome. Blood. 1997 May 1;89(9):3371-7.